A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistence

被引：0
|
作者：
Dignass, A. [1 ]
Gisbert, J. P. [2 ]
Bossa, F. [3 ]
Kelly, O. [4 ]
Rahman, M. [5 ]
Lobaton, T. [6 ]
Addison, J. [7 ]
机构：
[1] Goethe Univ, Agaples Markus Hosp, Dept Med 1, Frankfurt, Germany
[2] Univ Autonoma Madrid UAM, Hosp Univ La Princesa, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Madrid, Spain
[3] Fdn Casa Sollievo Sofferenza, Div Gastroenterol, IRCCS San Giovanni Rotondo, Puglia, Italy
[4] Connolly Hosp, Dept Gastroenterol, Dublin, Ireland
[5] Surrey & Sussex Healthcare NHS Trust, Dept Gastroenterol, Surrey, England
[6] Ghent Univ Hosp, Dept Internal Med & Pediat, Dept Gastroenterol, Ghent, Belgium
[7] Biogen Idec Ltd, Clin Res, Maidenhead, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P431
引用
收藏
页码：558 / 559
页数：2
相关论文
共 46 条
  • [31] Lomitapide in the long-term real-world management of HoFH - effectiveness, tolerability, and hepatic safety from the Pan-European study
    Cegla, J.
    d'Erasmo, L.
    Steward, K.
    di Costanzo, A.
    Boersma, E.
    Arca, M.
    van Lennep, J. Roeters
    ATHEROSCLEROSIS PLUS, 2022, 49 : S2 - S3
  • [32] Long-term real-world evidence of SB5 (adalimumab biosimilar) treatment in patients with moderate-to-severe psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
    Girolomoni, Giampiero
    Feldman, Steven R.
    Egeberg, Alexander
    Puig, Luis
    Jung, Jinah
    Jung, Hojung
    Lee, Younju
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [33] IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Genovese, M. C.
    Weinblatt, M.
    Keystone, E.
    Baranauskaite, A.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234
  • [34] 'BENEFIT' Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
    Selmi, Carlo
    Kruger, Klaus
    Cantagrel, Alain
    Hernandez, Abad
    Freudensprung, Ulrich
    Rezk, Mourad Farouk
    Addison, Janet
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [35] Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study (vol 11, pg 573, 2024)
    Fautrel, Bruno
    Bouhnik, Yoram
    Salliot, Carine
    Carbonnel, Franck
    Fumery, Mathurin
    Bernardeau, Christophe
    Maugars, Yves
    Flamant, Mathurin
    Coury, Fabienne
    Braithwaite, Ben
    Hateb, Salima
    Addison, Janet
    PERFUSE Investigators
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 163 - 164
  • [36] Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
    Ashina, Messoud
    Mitsikostas, Dimos D.
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Schankin, Christoph J.
    Sahin, Gurdal
    Pozo-Rosich, Patricia
    Dorman, Paul J.
    Nezadal, Tomas
    Poole, Anne Christine
    Martins, Isabel Pavao
    Sumelahti, Marja-Liisa
    Campos, Verena Ramirez
    Ahn, Andrew H.
    Lyras, Leonidas
    Tassorelli, Cristina
    CEPHALALGIA, 2023, 43 (11)
  • [37] LOMITAPIDE IN THE LONG-TERM REAL-WORLD MANAGEMENT OF HOFH - EFFECTIVENESS, TOLERABILITY, AND HEPATIC SAFETY DATA FROM THE PAN-EUROPEAN STUDY
    D'Erasmo, L.
    Steward, K.
    Di Costanzo, A.
    Boersma, E.
    Arca, M.
    Van Lennep, J. E. Roeters
    ATHEROSCLEROSIS, 2022, 355 : E27 - E27
  • [38] A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Sitek-Ziolkowska, Karina
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Zhdan, Vyacheslav
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [39] The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness
    Tassorelli, Cristina
    Barbanti, Piero
    Finocchi, Cinzia
    Geppetti, Pierangelo
    Kokturk, Pinar
    Russo, Antonio
    Sacco, Simona
    Cepparulo, Mario
    NEUROLOGICAL SCIENCES, 2024, 45 (05) : 2353 - 2363
  • [40] SECONDARY EFFICACY RESULTS UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMIAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Kay, J.
    Weinblatt, M.
    Keystone, E.
    Genovese, M. C.
    Baranauskaite, A.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 231 - 231
12345